Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brand/Generic Settlements May Get Supreme Court Review In Tamoxifen Case

Executive Summary

The U.S. Supreme Court may take up the question of whether reverse settlements between brand and generic companies can violate antitrust laws

You may also be interested in...



Brand/Generic Settlements Bill May Pass, But Industry Sees Room To Maneuver

Recently introduced House legislation, while prohibiting "reverse" payments by brand pharmaceutical companies to delay generic launches, would be far more palatable to industry than its Senate counterpart because it confines potential violations to the Federal Trade Commission Act, according to Pfizer Corporate Counsel Dara Diomande

Brand/Generic Settlements Bill May Pass, But Industry Sees Room To Maneuver

Recently introduced House legislation, while prohibiting "reverse" payments by brand pharmaceutical companies to delay generic launches, would be far more palatable to industry than its Senate counterpart because it confines potential violations to the Federal Trade Commission Act, according to Pfizer Corporate Counsel Dara Diomande

Brand/Generic Settlements Bill Clears Senate Cmte., Awaits Day On The Floor

After relatively smooth sailing through the Senate Judiciary Committee, legislation to prohibit "reverse payments" in brand/generic settlements now faces the challenge of securing floor-time for consideration by the full chamber

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel